Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

(2010) Gregory L. Moore et al.   mAbs

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

(2009) Jorge Castillo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

(2008) M. Luqman et al.   BLOOD

The impact of Fc engineering on an anti-CD19 antibody: increased Fc  receptor affinity enhances B-cell clearing in nonhuman primates

(2008) J. Zalevsky et al.   BLOOD

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40

(2008) E Oflazoglu et al.   BRITISH JOURNAL OF CANCER

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS